Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8 Receivables Turnover is 4.66 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, BPH Global ranks better than 80.63% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BPH Global's Revenue for the
six
months ended in Dec. 2025 was A$1.38 Mil. BPH Global's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.30 Mil.
Hence, BPH Global's Receivables Turnover for the
six
months ended in Dec. 2025 was 4.66.
BPH Global (ASX:BP8) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BPH Global Receivables Turnover Related Terms
BPH Global Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BPH Global's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BP8 vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BPH Global's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a Receivables Turnover of 4.66 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BPH Global and its competitors. According to the industry distribution chart, BPH Global ranks #184 out of 950 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is BPH Global's Receivables Turnover too high?
BPH Global's current Receivables Turnover is 4.66. The Drug Manufacturers industry median Receivables Turnover is 5.07. BPH Global's value of 4.66 is 8.1% below this industry median. Based on the distribution chart, BPH Global ranks #184 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BPH Global's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #184 out of 950 companies for Receivables Turnover. This places BPH Global in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. BPH Global's value of 4.66 is 8.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current Receivables Turnover of 4.66 is 8.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Receivables Turnover is 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Receivables Turnover of 4.66. The current Receivables Turnover is 4.66 and 8.1% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Receivables Turnover is 4.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
